THROUGH UNIVERSITY RESEARCH AND DEVELOPMENT
With teams at Western University and the University of Waterloo, CanaQuest Medical Corp has created a number of patentable product formulations. Our research and product development focuses on health products and nutraceuticals utilizing cannabis and botanical oil extracts including algae oils.
PRODUCT FORMULATIONS
A critical mass of clinical evidence regarding the efficacy of medical cannabis is refuting political, scientific, and other skeptics, and opening minds hardened by decades of anti-cannabis propaganda. Our goal is to develop better alternative treatments to traditional pharmaceuticals for people struggling with a variety of health challenges.
CQ1
Effective for anxiety, depression, schizophrenia, and more.
CQ2
Effective for anxiety, PTSD (chronic stress induced), pain and addiction.
CQ3
Effective for therapies for specific mental health symptom clusters.
CQ4
Effective for mitigation of the spread of cancerous tumors.
FOCUS AREAS
Anxiety
Addiction
Depression
Schizophrenia
PTSD
Pain
OUR VISION
Our vision is to be a global leader in the formulation and development of health products from cannabis derivatives.
IN THE NEWS
CanaQuest Medical Corp has been selected as a Global Awards Finalist by the International Trade Council
Research & development a primary focus for this medical cannabis company TORONTO, Aug. 15, 2019 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: "CANQF") (the "Company" or "CanaQuest"), announces it has been selected as a Global Awards [...]
CanaQuest Medical Corp Joins the Stock Day Podcast to Discuss Their Rapid Growth Plan
PHOENIX, AZ / ACCESSWIRE / July 22, 2019 / The Stock Day Podcast welcomed CanaQuest Medical Corp (OTC PINK: CANQF) (“the Company”), a company engaged in the development of unique health products and nutraceuticals that utilize hemp, [...]
CanaQuest Medical Corp Announces Filing of Cannabis/Botanical Provisional Patents
UNIQUE BOTANICAL AND TETRAHYDROCANNABINOL (“THC’) FORMULATION TREATING PSYCHIATRIC DISORDERS WITHOUT THE NEGATIVE PSYCHIATRIC SIDE-EFFECTS OF THC TORONTO, Feb. 05, 2019 -- CANAQUEST MEDICAL CORP (fka ALGAE DYNAMICS CORP) (OTC: “ADYNF”) (the "Company" or “CanaQuest”), a company developing [...]